Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program

Journal of Obstetrics and Gynaecology Canada

Volumn 37, Issue 5, 2015, Pages 412-420

  Coldman, Andrew J ^a   Phillips, Norm ^a   van Niekerk, Dirk ^a   Smith, Laurie ^a   Krajden, Mel ^b   Cook, Darrel ^a   Quinlan, David J ^c   Ehlen, Thomas ^c   Miller, Dianne ^c   Stuart, Gavin C E ^c   Peacock, Stuart ^a   Martin, Ruth Elwood ^c   Franco, Eduardo L ^d   Ogilvie, Gina ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

Cervical cancer screening; Colposcopy; HPV

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANCER SCREENING; CLINICAL PRACTICE; COLPOSCOPY; CYTOLOGY; FEMALE; HEALTH CARE UTILIZATION; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; PATIENT REFERRAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UTERINE CERVIX CANCER; WART VIRUS; CYTODIAGNOSIS; EARLY DIAGNOSIS; EMERGENCY HEALTH SERVICE; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PROCEDURES; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; UTERINE CERVICAL NEOPLASMS; VAGINA SMEAR;

ADULT; AGED; BRITISH COLUMBIA; COLPOSCOPY; CYTODIAGNOSIS; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; REFERRAL AND CONSULTATION; SENSITIVITY AND SPECIFICITY; TRIAGE; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 84939434041     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(15)30255-3     Document Type: Article

References (33)

1. Sasieni P., Cuzick J. Could HPV testing become the sole primary cervical screening test?. J Med Screen 2002, 9(2):49-51.
2. Cuzick J., Arbyn M., Sankaranarayanan R., Tsu V., Ronco G., Mayrand M.H., et al. Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries. Vaccine 2008, 26(Suppl 10):K29-K41.
3. Franceschi S., Denny L., Irwin K.L., Jeronimo J., Lopalco P.L., Monsonego J., et al. Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011, 128(12):2765-2774.
4. Murphy J., Kennedy E., Dunn S. Fung Kee Fung M, Gzik D, McLachlin CM, et al. Cervical screening: a guideline for clinical practice in Ontario 2011, Toronto (ON), Cancer Care Ontario, Available at:, Accessed December 19, 2013. https://www.cancercare.on.ca/common/pages/UserFile.aspx?fileId=124511.
5. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006, 119(5):1095-1101.
6. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007, 357(16):1579-1588.
7. van den Akker-van Marie M.E., van Ballegooijen M., Rozendaal L., Meijer C.J.L.M., Habbema J.D. Extended duration of the detectable stage by adding HPV test in cervical cancer screening. Br J Cancer 2003, 89:1830-1833.
8. Dillner J., Rebolj M., Birembaut P., Petry K.U., Szarewski A., Munk C., et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008, 337:a1754.
9. Elfgren K., Rylander E., Radberg T., Strander B., Strand A., Paajanen K., et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005, 193(3Pt 1):650-657.
10. Kitchener H.C., Almonte M., Thomson C., Wheeler P., Sargent A., Stoykova B., et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol 2009, 10(7):672-682.
11. Leinonen M.K., Nieminen P., Lonnberg S., Malila N., Hakama M., Pokhrel A., et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ 2012, 345.
12. Rijkaart D.C., Berkhof J., Rozendaal L., van Kemenade F.J., Bulkmans N.W., Heideman D.A., et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012, 13(1):78-88.
13. Ronco G., Dillner J., Elfstrom K.M., Tunesi S., Snijders P.J., Arbyn M., et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomized controlled trials. Lancet 2013, 383(9916):524-532. Available at:,Accessed February 24, 2015. http://ac.els-cdn.com/S0140673613622187/1-s2.0-S0140673613622187-main.pdf?_tid=ce92aeaa-68e8-11e3-b15a-00000aab0f01&acdnat=1387483666_eec34f0cdb006bdbeae75ea2374b83da.
14. Pollock S., Dunfield L., Shane A., Kerner J., Bryant H., et al. Recommendations on screening for cervical cancer. CMAJ 2013, 185(1):35-45. Canadian Task Force on Preventive Health Care.
15. Ogilvie G.S., Krajden M., van Niekerk D.J., Martin R.E., Ehlen T.G., Ceballos K., et al. Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial-the HPV FOCAL Study. Br J Cancer 2012, 107(12):1917-1924.
16. Rijkaart D.C., Berkhof J., van Kemenade F.J., Coupe V.M., Hesselink A.T., Rozendaal L., et al. Evaluation of 14 triage strategies for HPV DNA-positive women in population-based cervical screening. Int J Cancer 2012, 130(3):602-610.
17. Dillner J. Primary human papillomavirus testing in organized cervical screening. Curr Opin Obstet Gynecol 2013, 25(1):11-16.
18. Ogilvie G.S., van Niekerk D.J., Krajden M., Martin R.E., Ehlen T.G., Ceballos K., et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010, 10:111.
19. Solomon D., Davey D., Kurman R., Moriarty A., O'Connor D., Prey M., et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 2002, 287(16):2114-2119.
20. Anderson G.H., Boyes D.A., Benedet J.L., Le Riche J.C., Matisic J.P., Suen K.C., et al. Organisation and results of the cervical cytology screening programme in British Columbia, 1955-85. Br Med J (Clin Res Ed) 1988, 296(6627):975-978.
21. Cuzick J., Szarewski A., Cubie H., Hulman G., Kitchener H., Luesley D., et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003, 362(9399):1871-1876.
22. Bulkmans N.W., Rozendaal L., Snijders P.J., Voorhorst F.J., Boeke A.J., Zandwijken G.R., et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004, 110(1):94-101.
23. Program Cervical Cancer Screening Screening for cancer of the cervix: an office manual for health professionals 2012, Vancouver (BC), BC Cancer Agency, Available at:, Accessed December 19, 2013. http://www.screeningbc.ca/NR/rdonlyres/4545C16F-3F34M96C-ABF4-CB4B9BA04076/63243/CCSPmanual_Mar2013_Sma111.pdf.
24. Lawless J. Statistical models and methods for lifetime data 1982, John Wiley, New York. 1st ed.
25. Louvanto K., Chevarie-Davis M., Ramanakumar A.V., Franco E.L., Ferenczy A. HPV testing with cytology triage for cervical cancer screening in routine practice. Am J Obstet Gynecol 2014, 210(474):e1-e7.
26. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J.M., et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis 2012, 16(3):175-204.
27. Gertig D., Brotherton J., Budd A., Drennan K., Chappell G., Saville A. Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013, 11(227). 10.1186/1741-7015-11-227.
28. Franco E.L., Mahmud S.M., Tota J., Ferenczy A., Coutlee F. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: the need for a paradigm change. Arch Med Res 2009, 40(6):478-485.
29. Kyrgiou M., Arbyn M., Martin-Hirsch P., Paraskevaidis E. Increased risk of preterm birth after treatment for CIN. BMJ 2012, 345.
30. Arbyn M., Kyrgiou M., Simoens C., Raifu A.O., Koliopoulos G., Martin-Hirsch P., et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ 2008, 337:a1284.
31. Kyrgiou M., Koliopoulos G., Martin-Hirsch P., Arbyn M., Prendiville W., Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis. Lancet 2006, 367(9509):489-498.
32. Castanon A., Brocklehurst P., Evans H., Peebles D., Singh N., Walker P., et al. Risk of preterm birth after treatment for cervical intraepithelial neoplasia among women attending colposcopy in England: retrospective-prospective cohort study. BMJ 2012, 345.
33. Brentnall A.R., Vasiljević N., Scibior-Bentkowska D., Cadman L., Austin J., Szarewski A., et al. A DNA methylation classifier of cervical precancer based on human papillomavirus and human genes. Int J Cancer 2014, 135(6):1425-1432.